News

TeraImmune, NIAID Partnership Extended to Boost Treg Therapies

TeraImmune is extending its collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to continue developing regulatory T-cell-based therapies for multiple sclerosis (MS) and other autoimmune diseases. The extension will let the company continue optimize the manufacturing process for its lead regulatory T-cell (Treg) product in…

How ‘Medical Gaslighting’ Affects Women With Chronic Illness: Study

Women with chronic health conditions like multiple sclerosis (MS) often experience disbelief and disenfranchisement from healthcare providers when they seek care, a new study highlights. The study, “Women’s Experiences of Health-Related Communicative Disenfranchisement,” was published in Health Communication. There is a long history of discrimination and…

PoNS Device Now Available Online to Patients in US

People with multiple sclerosis (MS) in the U.S. now may order a Portable Neuromodulation Stimulator (PoNS) device online through a new e-commerce site launched by the device’s developer, Helius Medical Technologies. The website, built in partnership with the telehealth company UpScript, marks the first time…

Trial Testing Safety, Efficacy of Ginger Supplements in RRMS

Researchers in Iran are conducting a clinical trial to test the effects of taking ginger supplements for people with relapsing-remitting multiple sclerosis (RRMS). Ginger extracts have shown some promise in animal models of multiple sclerosis (MS), but no trial has yet determined the impact that ginger supplements may…

EDSS Score Drop of 1 Point Seen in 2nd SPMS Patient on Foralumab

A second person with non-active secondary progressive multiple sclerosis (SPMS) treated with foralumab nasal spray in a single-patient access program is continuing to show improvements 11 months after starting the therapy, according to an update from foralumab’s developer, Tiziana Life Sciences. The patient, dubbed EA2, experienced a…

Alcohol Consumption Is No Protection From MS: UK Study

The risk of developing multiple sclerosis (MS) doesn’t seem to be influenced by consuming alcohol, according to a large-scale analysis in the U.K. After adjusting for known MS risk factors, including smoking, childhood obesity, socioeconomic status, or genetics, the findings remained the same. The analysis was published in Nature…

Top 10 MS Stories of 2022

Multiple Sclerosis News Today brought consistent coverage of the latest scientific research, developments in treatment, and clinical trials for multiple sclerosis (MS) throughout 2022. This is a list of the top 10 most-read articles we published this past year, with a brief description of each. We look forward…

Ublituximab, Now Briumvi, Approved in US for Relapsing Forms of MS

The U.S. Food and Drug Administration has approved TG Therapeutics‘ B-cell-depleting therapy ublituximab under the brand name Briumvi for the treatment of adults with relapsing forms of multiple sclerosis (MS), the company announced. The approval covers clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive…

Stem Cell Transplant More Effective for SPMS Than Medications: Study

A stem cell transplant more effectively slowed disability worsening in people with active secondary progressive multiple sclerosis (SPMS) than anti-inflammatory treatments and disease-modifying therapies (DMTs), a study has found. More transplant recipients also experienced clinical improvements that were sustained after three and five years. After 10 years,…

Myelin Provides Metabolic Support to Inhibitory Brain Cells: Study

Myelin, the fatty-rich material surrounding nerve fibers that’s progressively damaged in multiple sclerosis (MS), provides metabolic support to a type of nerve cell in the brain that controls the activity of other nerve cells, a study discovered. Researchers showed mitochondria, the cell’s energy producers, are specifically clustered in…

Lcn-2 Protein Marks Intestinal Inflammation in MS, Study Shows

People with relapsing-remitting multiple sclerosis (RRMS) have elevated levels of the lipocalin 2 (Lcn-2) protein in their stool samples, a marker for intestinal inflammation, compared with healthy controls, a study demonstrated. Among patients, findings also demonstrated those with high fecal Lcn-2 had changes in their gut microbiome, the collection…

MS TreatSim Program Allows Simulation of RRMS Clinical Trials

Researchers have created a computer program that can simulate clinical trial responses for relapsing-remitting multiple sclerosis (RRMS), which may improve clinical trial design for novel disease-modifying therapies. The tool, called MS TreatSim, was described in the study, “In silico clinical trials for relapsing-remitting multiple sclerosis…

Testing for 4 Gene Variations May Predict Risk of PML Brain Infection

Genetic variations in certain genes may increase the risk of developing progressive multifocal leukoencephalopathy (PML), a serious brain infection associated with certain treatments for multiple sclerosis (MS) and other conditions, a new study shows. The findings suggest that testing for four specific genetic variant could help to predict…

New Machine Learning Algorithm May Better Predict Severity in MS

A machine learning algorithm that incorporates genetic data alongside clinical and demographic information may be able to more accurately predict the severity of multiple sclerosis (MS), according to a new study. “Once independently validated, the machine learning algorithm could enable clinicians to provide patients with more accurate prognostic information,…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here